BridgeBio Pharma (NasdaqGS:BBIO) FY Earnings Call Presentation

Commercial Momentum & Patient Impact - Attruby achieved $146 million in Q4 2025 net product revenue[16] - Attruby had 6,629 unique U S patient prescriptions[19] - Attruby's estimated share of NBRx is greater than 25%[19] Clinical & Regulatory Progress - BBP-418 showed a 1 8x increase in glycosylated αDG at 3 months and an 82% decrease in CK at 12 months[46] - BBP-418 treated patients experienced a clinically meaningful 2 6 point benefit on NSAD relative to placebo at 12 months[51] - The FDA recommended orienting the NDA for BBP-418 toward traditional approval[54] - Encaleret achieved a 76% responder rate in the CALIBRATE trial, demonstrating superiority to conventional therapy[60, 62] - Over 1,700 unique patients were diagnosed with ADH in the U S over a 24-month period[67] Pipeline Development - A new antibody depleter program was announced for ATTR-CM[30] - The Phase 3 trial for Infigratinib in achondroplasia achieved Last Patient Last Visit (LPLV)[81] - GondolaBio's PORT-77 in EPP demonstrated approximately 75% reduction in Plasma PPIX at high dose in Phase 2a trial[126] Financial Position - BridgeBio ended 2025 with $587 5 million in cash, cash equivalents, and marketable securities[141]